{"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.1942","statisticalMethod":"Cochran-Mantel-Haenszel"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"68.7","upperLimit":"80.4","value":"74.9"},{"groupId":"OG001","lowerLimit":"65.2","upperLimit":"77.4","value":"71.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"227"},{"groupId":"OG001","value":"225"}],"units":"Participants"}],"description":"Percentage of participants with a BOR of either CR or PR based on IRC review recorded from the start of treatment until disease progression based on RECIST v1.1. CR: disappearance of all target lesions (TLs), non TLs; any pathological lymph nodes (LN) must reduce in short axis to \\<10 mm; normalization of tumour marker level, for non TL all LN must be non-pathological in size (\\<10 mm short axis); PR:\\>=30% decrease in sum of diameters of TLs, referring baseline sum diameters. PD:\\>=20% increase in sum of diameters of TLs, referring smallest sum on study, sum must be an absolute increase of \\>=5 mm, appearance of \\>=1 new lesions; unequivocal progression of existing non TLs.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received 45 mg of dacomitinib tablets orally once daily in each treatment cycle of 28 days, up to a maximum of 48 months until disease progression, intolerable toxicities, withdrawal, death, or investigator decision dictated by protocol compliance, whichever occurred first.","id":"OG000","title":"Dacomitinib"},{"description":"Participants received 250 mg of gefitinib tablets orally once daily in each treatment cycle of 28 days, up to a maximum of 48 months until disease progression, intolerable toxicities, withdrawal, death, or investigator decision dictated by protocol compliance, whichever occurred first.","id":"OG001","title":"Gefitinib"}],"paramType":"NUMBER","populationDescription":"ITT Population included all randomized participants, with study treatment assignment designated according to initial randomization, regardless of whether participants received study treatment or a different treatment from that to which they were randomized.","reportingStatus":"POSTED","timeFrame":"Day 28 of Cycle 1, Cycle 2 then every 8 weeks until disease progression (up to 48 months)","title":"Objective Response Rate (ORR) Based on IRC Review","type":"SECONDARY","unitOfMeasure":"percentage of participants"}